Pharmaceuticals have been high-yield names in the last few years, especially as the approaching patent expiration cliff sent share prices down to discount levels. Merck (MRK) has been no exception; the $133 billion pharmaceutical maker currently pays out a 3.9% dividend yield.
Merck lost patent protection on its blockbuster asthma drug Singulair this year, a big blow to the firm to be sure. But investors have been bracing for the impact of patent expirations, and strategic moves such as the 2009 acquisition of Schering-Plough give Merck the late stage pipeline it needs to help replace that revenue loss. As I write, nearly half of the firm's sales come from the domestic market. And that's a very good thing right now considering the resilience of the U.S. dollar (that effectively penalizes overseas earnings) and the impact that "Obamacare" will have on pharmaceutical volumes in the next few years.A balance sheet that carries a nearly $3 billion net cash position gives Merck ample dry powder to get opportunistic with mergers and drug acquisitions in 2013. If the Singulair patent loss plays out to be less dramatic than anticipated, investors could lessen the discount on patent expirations going forward. That would be a very good thing for shareholders this year. To see these stocks in action, check out the at Dogs of the Dow portfolio on Stockpickr. -- Written by Jonas Elmerraji in Baltimore.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV